A Caenorhabditis elegans p38 MAP kinase pathway mutant protects from dopamine, methamphetamine, and MDMA toxicity.
Matthew A Schreiber, Steven L McIntire
Neuroscience Letters July 1, 2011 DOI: 10.1016/j.neulet.2011.04.071 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Forward genetic screen in a model organism Peer reviewed |
|---|---|
| Population | Caenorhabditis elegans nematodes |
| Interventions | Dopamine Methamphetamine MDMA 6-hydroxydopamine |
| Topics | MDMA |
| Key points | A mutation in the nsy-1 gene conferred resistance to dopamine, methamphetamine, and MDMA toxicity, and to 6-hydroxydopamine damage of dopaminergic neurons in a C. elegans Parkinson's disease model. The authors suggest the conserved p38 MAP kinase pathway may play a role in biogenic amine toxicity from amphetamines and in Parkinson's disease pathogenesis in higher organisms. |
Abstract
Biogenic amine systems are damaged by amphetamine abuse and in Parkinson's disease. The mechanisms mediating this damage are of high importance because of the public health impact of these problems. Here we have taken advantage of the Caenorhabditis elegans nematode model system to investigate genetic modifiers of biogenic amine toxicity. In a forward genetic screen, we identified a mutant resistant to the toxic effects of dopamine. This mutant was also resistant to toxic doses of methamphetamine (MA) and 3,4-methylenedioxymethamphetamine (MDMA). In addition, this mutation conferred resistance to 6-hydroxydopamine damage to dopaminergic neurons in a Parkinson's disease model. Resistance was due to a mutation in the nsy-1 gene, orthologous to the mammalian ASK-1 MAPKKK. NSY-1 is in the highly conserved p38 MAP kinase pathway, which plays a crucial role in C. elegans innate immunity, suggesting that this pathway may play a role in biogenic amine toxicity system damage due to amphetamines and in the pathogenesis of Parkinson's disease in higher organisms.
Citations in the library
Cited by 3
- Utilizing Caenorhabditis Elegans as a Rapid and Precise Model for Assessing Amphetamine-Type Stimulants: A Novel Approach to Evaluating New Psychoactive Substances Activity and Mechanisms. Advanced Science May 1, 2025
- Sublethal Concentrations of 2C-I and 25I-NBOMe Designer Drugs Impact Caenorhabditis elegans Development and Reproductive Behavior. International Journal of Molecular Sciences March 26, 2025
- Advances in drug addiction research using Caenorhabditis elegans: behavioral and molecular mechanisms. Frontiers in Cell and Developmental Biology 2026
Cites 4
- Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. Journal of Pharmacology and Experimental Therapeutics 1987
- 3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites. Journal of Pharmacology and Experimental Therapeutics September 1, 1987
- 3,4‐Methylenedioxymethamphetamine (MDMA, “Ecstasy”): pharmacology and toxicology in animals and humans Addiction May 1, 1994
- Amphetamine toxicities Annals of the New York Academy of Sciences January 8, 2010